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INTRODUCTION 
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INTRODUCTION 
 Preterm or premature birth are terms used to define neonates born 
before 259 days is considered as largest contributor to infant mortality and 
morbidities. 
 A variety of morbidities are largely due to organ system immaturity, 
are significantly increased in infants born before 37 weeks gestation 
compared with those delivered at term. 
Children who are born prematurely have a higher risk of cerebral       
palsy, sensory deficits, learning disabilities and respiratory illness than 
those born at term. 
Beck and collegues (2010) estimated that 9.6% of all births were       
preterm in 2005,which accounts about 12.9million birth. About 85% of 
this were in Asia  and Africa where 10.9 million births were preterm. 
Very often ,the diagnosis of preterm labour is made at too advanced 
stage in labour to effectively stop it or act upon it.This appears to be true 
in developed and in developing countries. 
Despite advances in perinatal medicine recent decades the problem 
of  Preterm birth continues to frustrate satisfactory reproductive outcomes 
2 
 
with little progress having been made in identifying and  reducing the 
frequency of Preterm . 
A real reduction in the preterm delivery rate will only take place         
through an improved understanding of the etiology, pathogenesis, identify 
the patient at risk, prediction of preterm labour and its early detection and 
effective  tocolysis. 
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 Resources used to care for preterm infants are measure of the social 
burden of preterm birth. Amount spend is immeasurable. So preterm 
labour Should be prevented.  Pharmacological  inhibition of preterm 
labour remains the most effective means to delay delivery and improve the 
neonatal Outcome until a more effective means of prevention is identified. 
Our study is concerned to detect a better drug among transdermal 
patch of nitroglycerine and oral nifedipine in the prevention of preterm 
labour. 
  
AIM OF THE STUDY 
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AIM OF THE STUDY 
 To compare the safety and efficacy of oral nifedipine with 
transdermal patch of nitroglycerine in the tocolysis of preterm labour. 
  
OBJECTIVE OF THE STUDY 
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OBJECTIVE OF THE STUDY 
 To detect a better drug  in the achievement of the tocolysis of 
preterm labour. 
  
REVIEW OF LITERATURE 
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DEFINITION  : 
Pre term labour is defined as the presence of uterine contractions of 
sufficient strength and frequency to cause progressive effacement and 
dilatation of the cervix between 20 weeks and 37 weeks or before 259 
days(acc. To WHO ).
72
 
 Based on the gestational age the preterm birth can be classified
44
 in 
to: 
Extremely preterm   -      < 28 weeks. 
           Very preterm                              -       28  to <32 weeks. 
           Moderate  preterm                      -       32 to 34  weeks. 
           Late preterm                               -        34 to 36 weeks    
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Fetal viability period lower limit are the following 
1,65
 : 
 
 UNITED STATES – 20 WEEKS ( ACOG 1995) 
 ROYAL COLLEGE OF OBSTETRICIAN -24 WEEKS 
 FIGO- 22 WEEKS 
 INDIA- 28 WEEKS 
 INCIDENCE : 
          Preterm delivery rate : 
United states – 11% 
           Europe 5 – 7 % 
           India -12.3% (NNPD ) 
1 in 5 pregnant women exhibit signs and symptoms  of preterm 
labour 
MAGNITUDE OF THE PROBLEM : 
 Large no of perinatal mortality and morbidity occurs due to preterm 
labour 
 About 75 – 90 % of neonatal death is due to preterm labour 
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 20% of all infants born< 32 weeks donot survive the first year of life 
 The infant mortality rate for very pre term infants (deliverd <32 
weeks of gestation) is nearly 75 times the rate for infant born at                          
term.
53
 
 It is the second leading cause of death after pneumonia in children 
under five years of age. 
 Recently  the primary focus is on late preterm  infants between 34 
and 36 weeks because of increased morbidity rates compared with 
those at term. 
 These infants predominantly suffer not only the immediate 
complications of  prematurity but also long term disabilities like 
neurodevelopmental disabilities. 
PRETERM MORBIDITY
55
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PRETERM  MORTALITY 
 
 
 
 
 
 
 
 
 
 
ETIOPATHOGENESIS OF PRETERM LABOUR 51: 
Activation of maternal or fetal HPA axis : 
30 percentage of preterm labour are due to this mechanism. 
This is mainly due to maternal fetal stress factor and premature  
onset of physiological initiators 
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Infection  : 
This is the most common etiology which accounts for about 40 %. 
Infections are mainly chorion –decidual and systemic infection 
Decidual hemorrhage : 
20% are due to this factor. 
Main contributing factor in this is abruptio placenta 
Pathological distension of uterus: 
10%of preterm labour are due to pathological distension. 
Causes of pathological distension are: 
Multiple pregnancy. 
Polyhydramnios. 
Uterine abnormalities 
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ETIOPATHOGESIS OF PRETERM LABOUR : 
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ACTIVATION OF MATERNAL OR FETAL HPA AXIS : 
 
`  
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INFECTION :  
 Infection or chorioamnionitis is associated with preterm labour was 
first recognized by Bobitt and Ledge
.18,19
 
 
 
 
  
14 
 
Intrauterine infection is considered to have following stages 
34,35,36
 : 
 STAGE I – infection in the vaginaand cervix. 
 STAGE II – deciduitis. 
 STAGE III  -    choriovasculitis or amnionitis. 
 STAGE IV -    finally infection of the fetus. 
12.8 % of pretem labour shows positive for infection of amniotic fluid by    
culture (e76 Neoreviews vol 3no 5.may 2002). 
Two important pathogens: 
 Mycoplasma hominis 
Ureaplasma urealyticum   are associated with preterm labour. 
Goldenberg and collegues (2008a)reported that 23%of neonates 
born between 23 and 32 weeks have positive umblical cord culture for the 
genital mycoplasma. 
Colonization of genital tract with the following organism are also  
found to be associated with preterm labour. 
 Chlamydia trichomatis (martin et al, Harrison et al) 
15 
 
 BACTERIAL VAGINOSIS – Gardenerella vaginalis , 
mobiluncus species mycoplasma hominis (Hiller and collegues 
1995). 
 Niesseria gonorrhea ( Edward et al). 
 Trichiomonias. 
 Group  B streptococcal  infection (Bobit et al ,Lamont et al). 
OTHER INFECTIONS : 
 Urinary tract infection associated with asymptomatic bacteriuria 
also associated with preterm labour. 
PERIODONTITIS :  Preterm birth is also associated with periodonitis by 
gram negative bacteria which mainly affect the connective tissue 
(Boggesss KA obg gyn 2003).
17 
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RISK  FACTOR  FOR PRETERM LABOUR : 
 
 
 
RISK FACTORS : (Arias F, Obstet Gynecol 1982;14;361)
11
 
 Iatrogenic preterm delivery 
MATERNAL : 
systemic medical illness 
substance abuse 
Severe preeclampsia or eclampsia 
 
18 
 
 
 UTERINE : 
Anomalous uterus 
Overdistension 
fibroids 
 PLACENTAL: 
Placental abruption,placenta previa 
          Marginal placental  bleeding,  
          Large chorioangioma 
 AMNIOTIC FLUID : 
Preterm ruputure  of chorioamniotic membranes 
          Polyhydramnios 
          Clinical chorioamnionitis 
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 FETAL : 
Fetal malformation 
          Multifetal gestation 
Fetal hydrops 
          Fetal growth restriction 
          Fetal demise 
 CERVICAL  
Incompetence of cervix 
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ANTECEDENT AND CONTRIBUTING FACTORS: 
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    The following are the antecedent and contributing factors : 
1. RECURRENT PRETERM: 
 A previous occurrence of preterm labour before 34 weeks increases 
the chance of recurrence (krymko et al).
55 
only ten percent of all preterm 
occur in women with previous preterm birth . 
2.  RACE : 
 Increased prevalence of preterm labour is seen in black women 
35,51
. 
Bacterial vaginosis is more commonly seen in the black people may   
explain this increased prevalence of preterm labour . 
Non-hispanic African American-17.8%  
           American Indians/Native Alaskans – 13.5% 
           Hispanics  - 11.9% 
           Whites  -   11.5% 
           Asian and pacific islandus 10.5%  (CDC : 2004 Birth) 
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3. LOW BODY MASS INDEX : 
 Over weight women are at decreased risk of preterm labour before 
35 weeks when compared to women with normal weight  (Ehrenberg and 
collegues 2009 ).
   
4. ABSENT OR INADEQUATE PRENATAL CARE 
 Poor ante natal care is associated with increased risk of preterm 
birth.
31
 
5. EXTREMES OF AGE : 
 It is more common in extremes  of age group. incidence is more in 
age group < / = 18 yrs and >/=35 years. 
6.  STRENOUS WORK: 
 This factor have increased risk of preterm birth (i.e) working for 
long hours like standing and walking and hard physical labour 
(Goldenberg and collegues 2008b).
35
 
7. SUBSTANCE ABUSE: 
 Negger and co worker 2004 
54
 found that substance abuse and 
smoking is have increased risk for preterm labour. 
23 
 
 Alcohol dependence syndrome 
59
 is also important contributing 
factor. 
8. THREATENED ABORTION: 
 Bleeding between 6 to 13 weeks have increased chance for preterm                
labour according to weiss and associates (2004).
 71
 
9.  BIRTH DEFECT   : 
           Birth defects were associated with preterm birth and low birth 
weight according to Dolan and collegues (2007
)  27
 in FASTER TRIAL. 
10. INTERVAL BETWEEN PREGNANCIES AND PRETERM 
BIRTH: 
 Conde Agudelo and co workers (2006) 
23
  reported that interval 
between the pregnancies  less than18 months and more than 59 months 
were associated with more chance forboth preterm birth and small for 
gestational age infants. 
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CLINICAL FACTORS USED TO PREDICT PRETERM LABOUR: 
RISK ASSESMENT: 
                Risk assessment is a concept first proposed by Papernik 
(pressmed 1969).
64
 
 Risk scoring system devised by papiernik and modified by creasy 
and Govik(1980)has been tested in several regions. 
The purpose of this is to identify the women at increased risk to give 
birth early prior to the onset of labour would lead to interventions that 
could prevent preterm birth the frequency of large number of 
dermographic and epidemiological markers in women who did and did not 
give birth were compared. 
 Unfortunately risk scores donot identify the majority of women who 
deliver Preterm. They are of limited clinical use. 
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CREASY AND COLLEGUES  
4 
 : (ObGyn  1980,1982,birth defect 
1983): 
 More simplified scoring system Scoring system is based on the 
factors which increases risk of preterm birth, the risk is more with 
recurrent preterm, bleeding in the pregnancy, UTI, high order pregnancies, 
body mass index < 20kg/m2, previous low birth weight and stress factors. 
Screening is performed during the prenatal care visits. 
Several studies have failed to show any benefits from risk scoring 
systems  
 >/= 10 high risk 
 5-9 medium risk 
 0-5 low risk 
 The prevalence of preterm labour was 6.1% 
 The sensitivity was 64% 
 Positive predictive value  30% 
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CERVICAL ASSESMENT : 
Asymptomatic cervical dilatation after midpregnancy is suspected           
as a risk factor. 
The odds ratio of preterm delivery was 1.43 for each unit increase in            
bishop score for nulliparous women and 1.23 for multiparous            
women(p<0.0005) 
           Cervical dilatation>/=1 cm,length <2 cm and cervical score,2, 
respective sensitivities and specificities of 8% and99%,13% and 93% and 
20% and93% respectively (hartmann k,obstet Gynecol1999:93:504-9) 
39
.  
Iams and co workers(1996) 
43 
 measured cervical length at 
approximately 35mm and those women with progressively shorter cervix 
experiences increased rate of  preterm birth. 
Ultrasound images of the cervix in preterm labour shows effacement 
as  early  as 16 to 24 weeks but this ultrasound finding is seen at 32 weeks 
in term pregnancy. 
FUNNELING: 
It is the ultrasound evidence of ballooning of the membranes into 
dilated internal os with closed external os .(owen et al 2003).
62
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A shortened cervix in association with funneling has been shown to 
be an indicator of greater risk of preterm delivery(Rust et al 2005).
66 
 
 
Decarvalho and co workers(2005) 
26
  concluded from the study 
conducted by them on 1958 women by sonographic examination that short 
cervix was poorest  predictor of preterm but funneling plus history or prior 
preterm birth was highly  predictive. 
ZILANTI ET AL 
73
 described the appearance of cervical effacement 
as seen by transvaginal sonography as following which describes the 
relationship of the cervical canal to the lower uterine segment. 
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T – Closed Uneffaced Cervix  Y – partial effacement from internal os   
                                    
 
 
 
 
 
 
v – further progression of               u -  membranes exposed through  
       effacement                    internal os in to the vagina 
 
 
 
 
 
 
DOPPLER VELOCIMETRY IN PREDICTING PRETERM 
LABOUR:(Rizzo et al 1996) 
 Decreased uteroplacental perfusion may predict preterm labour. 
Decreased P I in MCA and increased RI in uterine artery. 
 These have poor positive predictive value. 
29 
 
FETAL BREATHING MOVEMENT : 
 Absence of    fetal  breathing  movement in the ultrasound predicts 
preterm birth. labour with in 48 hrs. 
o Sensitivity  -  96.7% 
o Specificity – 80% 
o Positive predictive value -87.9% 
o Negative predictive value- 94.1% 
HOME UTERINE ACTIVITY MONITORING: 
In 1950,Alvarenz and Caldeyro Barci reported simply that “the 
uterus never sleeps”; “Alvarez waves” . Zahn identified an increase in 
uterine contractility between 10pm and 2 am among 54 normal women 
performing continuous 24 hour tocodynametry . Clinical trials have 
generally involved four different study methodologies: 
1. Self identification of preterm labour signs or symptoms. 
2. Frequent perinatal nursing contact. 
3. HUAM alone . 
4. Frequent perinatal nursing contact with HUAM. 
           This system is not recommended by ACOG
.2 
30 
 
FETAL FIBRONECTIN : 
 
Glycoprotein found in extracellular matrix of amniotic membranes        
Act as glue that binds chorion to deciduas. 
        Normally found in cervico vaginal secretions until 20weeks of 
gestation and again at the term released in to vaginal/cervical fluid in 
response to inflammation or separation of amniotic membranes from 
deciduas.  Presence after 24 weeks is indicative of imminent labour.   Fetal 
fibronectin immunoassay detects concentrations of fetal fibronectin protein 
in cervicovaginal fluid.   Presence of fetal fibronectin >50ng/ml 
50,51,53
 after 
22 weeks  is considered positive 
31 
 
 
OTHER MARKERS: 
SALIVARY ESTRIOL: 
           Normally there is increase in the level of estriol through out the 
pregnancy. This increase accelerates five weeks prior to uneventful 
delivery. Estriol level greater than 2.1ng/ml 
48 
 is considered positive.           
This test becomes unsuitable due to suppression by antenatal steroids and 
diurnal variation.  
ACTIVIN AND INHIBIN: 
           Releases the local prostaglandins 
32 
 
RELAXIN: involved in collagen remodeling with in amnion and chorion. 
Plevyak et al noted a significant effect with activin and inhibin levels only 
at 31-34 weeks further research is required. 
CORTICOTROPIN RELEASING HORMONE: 
Before the onset of preterm labour the level of CRH is increased.                 
Increased level of CRH 1.9MOM is used to anticipate the preterm birth                 
(Dudley DJ,AJOG 1999). 
PRO INFLAMMATORY CYTOKINES IL 6 : 
Cervical IL 6 and serum IL6 increased at a very high level at 24 
weeks of gestation  in women withspontaneous preterm labour before 35 
weeks of  gestation. 
Cervical IL 6 has strong association with levels >410pg/ml and has 
an RR of 7.7 for intraamniotic infection(Reece and hobbins 2007).
67 
OTHER INVESTIGATIONAL MARKERS: 
The NICHD MFMU’S preterm prediction study(1993-1996): 
This study found the predictors of preterm labour: 
           1. fetal fibronectin > 50ng/ml 
           2.cervical length </= 25 mm 
33 
 
Between 32 to 35 weeks predictors are: 
o Serum alpha feto protein 
o Alkaline phosphatase 
o G-CSF above 75th percentile. 
DIAGNOSIS OF PRETEM LABOUR: 
Preterm labour can be classified as threatened or actual   the basis 
for such classification is the difference in prognosis. Approximately 85% 
of patients with threatened preterm labour deliver after 37 weeks ,whereas 
40-50% of all patients in actual preterm labour deliver at term. 
THREATENED PRETERM LABOUR:  
Absence of cervical change in the presence of contractions.  
SYMPTOMS OF PRETERM LABOUR: 
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INGEMARSSON’S CRITERIA FOR PRETERM LABOUR: 
 Gestation  between 28-36 weeks 
 Painful, regular, uterine contractions occurring at interval of less 
than 10 min, for atleast 30 min, by external tocography 
 Intact membranes 
 Effacement of cervix with cervical dilatation between 1 and 4 
cms 
CREASY CRITERIA: 
 Gestation  age of 20 to 37 weeks 
 Documented uterine contractions 4 in 20 min or 8 in 60 min 
 Documented cervical changes or cervical effacement of 80% or 
dilatation of cervix greater than or equal to 2 cm 
 Intact membranes. 
 SPECULUM EXAMINATION: 
o To determine the length of the cervix and extent of dilatation of 
cervical os. 
o To  determine the presence of amniotic fluid. 
  
35 
 
 
DIGITAL EXAMINATION: 
o To be avoided if membranes have ruputured 
o Effacement and dilatation are looked for. 
PREVENTION OF PRETERM LABOUR 
As preterm labour is the major cause for the perinatal morbidity and 
mortality its prevention is an important strategy in the management of 
patients at high risk for preterm. 
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This prevention is achieved by: 
1. Antibiotics 
2. Cervical encerclage 
3. Progesterone. 
ANTIBIOTICS: 
Goldenberg et al 2008 
35  
postulated that infection may trigger by 
activating the innate immune system so control of infection plays an 
important role in the prevention of preterm labour. 
        A meta analysis by Bujold  and Morency (2007) 
56
 proposed that 
recurrence of preterm labour is reduced by administering antibiotics in the 
second trimester for women with history of preterm labour 
Carey et al (2000) 
21
 and okun et al (2005)  found that when women 
treated with metranidazole for bacterial vaginosis there was no significant 
reduction in preterm labour but reduction in persistant infection is found. 
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CERVICAL ENCERCLAGE: 
Encerclage as treatment for the preterm labour is found to be 
Controversial. 
 
 
 
 
 
 
THREE TYPES OF CERCLAGE: 
PRIMARY CERCLAGE: 
Done prophylactically in high risk patient 
SECONDARY CERCLAGE: 
Done in patients with USG evidence of cervical insufficiency 
 
38 
 
 
TERTIARY OR RESCUE CERCLAGE: 
Done as emergency procedure in patients with established  cervical 
incompetence. 
In CIPRACT TRIAL 2001 proved that cerclage reduced the rate of 
preterm labour in patient with gestational age<34 weeks(Althusius et al
) 3.
 
Berghella and colleagues 2005 
15
proposed that in patient with 
priorhistory of preterm labour cerclage reduced the rate of preterm labour. 
Daskalakis et al 2006 proved that the group who received cerclage 
benefitted with prolongation of pregnancy. Dor et al 1982 proved that 
cerclage provides no benefit in twin pregnancy and Triplets ( Roman et al 
2005.) 
PROGESTERONE: 
Intramuscular injection of 250 mg of 17 hydroxyprogesterone 
reduced the rate of preterm birth before 37 weeks when administered 
between 16 to 20 weeks (Meis et al).
54 
           No benefit in twin gestation according to Rouse et al 2007.  
39 
 
 
Intravaginal progesterone : 
Micronized progesterone capsules 200 mg vaginally have been used 
in trial in asymptomatic patient with cervix length less than 15 mm and 
appears to be effective (da fonseca et al 2007
).25
 
PROGESTERONE IS NOT RECOMMENDED : 
 As supplementary in cervical encerclage for suspected cervical 
insufficiency.             
 As a preventive for asymptomatic women with a positive 
fetalfibronectin screening. 
 As a tocolytic agent 
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MANAGEMENT 
STEP 1:              
THE EVALUATION PHASE: 
 The need and the specific nature for tocolytic therapy is assessed 
 An etiological diagnostic workup is carried out 
 To seek to rule out contraindications to substantially prolonging the 
pregnancy. 
 
STEP 2 : 
Next step is the decision about tocolytic to give. 
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STEP 3 : 
Ultrasound examination done in this step 
            
42 
 
ROLE OF BED REST ,HYDRATION AND SEDATION IN 
PRETERM LABOUR: 
BED REST: 
This is one of the most prescribed intervention during pregnancy. 
Many studies have proved no role of bed rest in the inhibition of preterm 
labour.
32 
HYDRATION AND SEDATION : 
Helfgott  
40
 and associates compared hydration ,sedation with bed 
rest and found no difference. 
TOCOLYTICS : 
 Drugs used in the suppression of preterm labour.  
 BETA ADRENERGIC AGONIST 
 MAGNESIUM SULFATE 
 PROSTAGLANDIN INHIBITORS 
 OXYTOCIN ANTAGONIST 
 CALCIUM CHANNEL BLOCKER  AND  
NITRIC OXIDE DONORS. 
43 
 
 
MECHANISM OF TOCOLYTICS : 
 
 
 
 
  
44 
 
BETA-SYMPATHOMIMETIC AGENTS 
Ritodrine, terbutaline, salbutamol  
5
 are the commonly used drugs. 
          These  are often associated with serious maternal side effects 
 Pulmonary edema. 
 Arrhythmia. 
The cause of pulmonary edema is multifactorial,and risk factors,   
include tocolytic therapy with beta agonist,multiple pregnancy,steroid 
therapy, Tocolysis for more than 24 hours,large intravenous crystalloid 
volume infusion. 
These drugs are potent cardiovascular stimulants and can cause 
serious  complications such as maternal myocardial ischemia, metabolic 
derangements like hyperglycemia and hypokalemia and fetal cardiac    
effects. 
BETA-SYMPATHOMIMETIC AGENTS(ADMINISTRATION) 
 Ritodrine infusions (Caritis and colleagues)  
50-100microgm/min, increase 50 microgm/min every 10 min until 
contraction ceases. 
45 
 
Ritodrine is no longer recommended as first line of drug by RCOG.
65 
Terbutaline : 
 In a commonly used regimen, 0.25 mg is given subcutaneously 
every 20 to 60min until contractions have subsided. 
 Oral: The usual daily dose ranges from 10 to 30mg,max:40mg 
PROSTAGLANDIN SYNTHETASE INHIBITORS 
Indomethacin 
74
 is commonly used drug 
 50 to  100 mg of  indomethacin administered once in 8 hrs for 24 
hrs. total. 
 dose should not exceed 200mg 
 After oral administration serum concentration peaks in 1 to 2 hours 
MATERNAL SIDE EFFECTS: 
 Nausea 
 Vomiting 
 Headache 
 Diarrhea 
46 
 
FETAL COMPLICATION: 
 Closure of ductus arteriosus 
 Pulmonary hypertension 
 Interventricular hemorrhage 
 Necrotizing entero colitis 
MAGNESIUM SULFATE 
28 ,68
: 
Mostly it act as calcium antagonist. It uncouple depolarization 
contraction coupling. It affects neural transmission modifying 
acetylcholine release and sensitivity at motor end plate. 
DOSAGE: 
           Loading dose 4 gm over 20 min followed by continuous infusion 
2g/hr. 
CRITICAL SERUM LEVEL OF Mgso4 : 
o Therapeutic range    – 6-8 mg/dl 
o Loss of deep tendon reflexes  – 8 -12 mg/dl 
o Respiratory paralysis    – 10 -15 mg / dl 
o Cardiac arrest               -  >20mg/dl 
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SIDE EFFECTS: 
a. Loss of deep tendon reflexes 
b. Warmth during infusion 
c. Increase in skin temperature 
d. Chest tightness 
e. Hypocalcemia 
f. Pulmonary edema 
          According to Grimes  and Nanda 2006 magnesium sulfate in 
ineffective as tocolytic 
Magnesium Sulfate has Cerebro Protective Action 
CALCIUM CHANNEL BLOCKERS: 
The most commonly used calcium channel blocker is nifedipine.
46,63
          
It act by inhibiting the influx of extracellular calcium across the cell 
membrane during inward calcium current of action potential. They block 
the voltage sensitive L type of calcium channels . They   also inhibit the 
release of intracellular calcium from sarcoplasmic reticulum. Thus  they 
reduce the tone of smooth muscles. 
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DOSAGE OF NIFEDIPINE:   most commonly used 
 20 mg orally stat 
 Followed by 20 mg orally after 60 min if contractions persist 
 Maintenance dose of 20 mg orally every 3-8 hrs for 48-72hrs 
 Maximum dose is 160 mg /day 
Onset of action after oral nifedipine is less than 20 min with peak 
plasma concentration in 1 hour(15-90 min) and half life of 1.5 to 3 hrs. 
duration of action of single dose is 6 hrs. Elimination is mainly through 
kidney(70%) and bowel (30%) nifedipine doesnot adversely affect 
uteroplacental and fetal blood flow when evaluated by Doppler  
SIDE EFFECTS: 
a. Facial flushing 
b. Nausea 
c. Headache 
d. Hypotension,  Tachycardia 
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NITROGLYCERIN 
20,22,47
: 
It causes smooth muscle relaxation 
Short duration of action.t1/2 is 2 min 
By following route it can be administered:  
i. Sublingual 
ii. Transdermal 
iii. Ointment 
iv. Oral capsule  extended form. 
DOSAGE: 
10 mg transdermal patch is applied over abdomen ,if contraction 
persist another patch applied for 24 hrs.Not more than 2 patches should be 
appliedsimultaneously.It does not reaches the fetal circulation. 
OXYTOCIN RECEPTOR BLOCKADE: 
Atosiban 
37 
is licensed in the UK for treatment of tocolysis preterm 
labour. 
The recommended dosage and administration schedule for atosiban 
is a three-step procedure. 
50 
 
The initial bolus dose is 6.75 mg over one minute, followed by an 
infusion of 18 mg/hour for three hours and then 6 mg/hour for up to 45 
hours. 
Duration of treatment should not exceed 48 hours and the total dose 
given during a full course should preferably not exceed 330 mg of 
atosiban. 
CORTICO STEROIDS IN PRETERM LABOUR; 
The incidence and severity of neonatal respiratory distress syndrome 
has significantly reduced with the use of antenatal steroids according to 
Cochrane database (Crowther CA 2007).
24 
The effects of corticosteroids are mediated by  way of intracellular 
corticosteroid receptors or corticosteroid-induced paracrine effects    
between cells. 
 Corticosteroids have been shown to stimulate the  cyto 
differentiation in fetal lungs and at least 14  other tissues.       
 Short-term neonatal benefits of maternal administration of antenatal 
corticosteroids include a decrease in the frequency of RDS, IVH, 
and neonatal mortality.  
51 
 
BETAMETHASONE OR DEXAMETHASONE: 
Betacode trial by Elimian and collegues (2007)  
30
 found that the 
two drugs were comparable in reducing in major neonatal morbidities in 
premature infant. 
DOSAGE :(RCOG 2004) 
65 
BETAMETHASONE:  2 doses of 12 mg given in IM 24 hours apart. 
DEXAMETHASONE: 4 doses of 6mg ,given IM 12 hours apart. 
 There is increased incidence of interventricular hemorrhage in the        
betamethasone group compared to dexamethasone group. 
 Antenatal exposure of betamethasone is associated with decreased 
incidence of  periventricular leukomalacia  but dexamethasone is 
associated with an increased incidence of periventricular 
leukomalacia. 
   single dose of corticosteroid is recommended  according to ACOG 
(committee opinion 402,2008). 
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what is rescue therapy ? 
 Administration of repeated corticosteroid dose when delivery 
becomes imminent and more than seven days elapsed since the initial 
dose. 
          Rescue therapy should not be routinely used recommended by 2000           
consensus development.
57,58 
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MATERIALS AND METHODS 
STUDY DESIGN: 
 It is a prospective study conducted in Government RSRM lying in 
Hospital attached to Stanley medical college, Royapuram from September 
2013 to 2014. 
The study population comprised of patients who attended either the 
hospital outpatient department or causality. 
There were 100 patients in transdermal NTG group in which 3 
patient lost follow up and one patient is still continuing pregnancy. 
There were 100 patient in oral  nifedipine group in which 3 patient 
lost follow up and 2 patients are still continuing pregnancy. 
Both the group received intramuscular corticosteroids. 
          In view of ethical issue informed written consent is obtained. 
INCLUSION CRITERIA: 
1. Gestational age between 28 and 36 completed weeks as determined 
by menstrual dates ,clinical examination, ultrasonagram abdomen. 
2. Singleton pregnancy. 
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3. Uterine contractions – regular and painful ,3 per 10 min each lasting 
for more than 40 to 45 secs. 
4. Progressive cervical effacement up to 75%. 
5. Cervical dilatation up to 3 cm. 
6. Intact membranes. 
EXCLUSION CRITERIA: 
Maternal Conditions: 
1.  Rupture of membranes 
2.  Infection. 
3.  Cervical dilatation greater than 3 cm 
4.  Antepartum hemorrhage 
5.  Polyhydramnios /oligohydramnios 
6.  Hypertension complicating pregnancy. 
7.  Cardiac disease. 
8.  Renal disease 
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9.  Pulmonary disorder- asthmatics, ARDS 
10.  Uncontrolled diabetes mellitus 
11.  Cervical incompetence 
12.  Treatment with another tocolytic agent in the previous 24 hours. 
Fetal Factors: 
1.  Multiple gestation 
2.  Fetal death 
3.  Fetal distress 
4.  Intra uterine growth restriction 
5.  Congenital anomalies.  
INVESTIGATIONS: 
 Urine analysis 
 Complete blood count 
 Vaginal swab 
 Ultrasound abdomen 
56 
 
DRUG PROTOCOL: 
On admission , patients are put in left lateral position and measured 
for blood pressure , pulse rate. cardio vascular system and respiratory 
system examined. 
Each patients received 12 mg of betamethasone intramuscularly, 
first dose is given at the time of admission and after 24 hours second dose 
is repeated to accelerate the fetal lung maturity. 
GROUP I  
Patients in this group receives transdermal NTG patch which 
delivers  10mg of NTG over 24 hours. 
If  contraction persist after 1 hour an additional patch is applied. 
Two patches (10 mg) should not be applied simultaneously. 
At the end of 24 hours fresh patches are applied. 
Mild headaches are treated with oral paracetomol. 
When the contraction ceases patches remain in the place for 12 
hours. 
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If the uterine contraction doesnot stops with two patches tocolysis is 
not achieved and treatment stopped. 
Achievement of tocolysis is considered when the contraction ceases 
and Prolongation of pregnancy atleast for 48 hours. 
GROUP II : 
Patients receive 20 mg of nifedipine as loading dose. 
When contraction persist even after one hour another 20 mg is 
given. 
If the contraction stops after the first or the second dose, 
maintanence dose of oral nifedipine 20 mg every 6 hours is given for the 
next 48hours. Maintanence dose started 6 hours after the last dose.  If the 
uterine contraction doesnot arrest even after the 40 mg of Nifedipine  then 
tocolysis is not achieved. 
Tocolysis is achieved when the contraction stops and no progression 
of cervical effacement and dilatation and prolongation of pregnancy atleast 
for 48 hours. 
Antibiotic  treatment should be given to the patient whenever 
necessary to control the infection. 
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VITALS TO BE MONITORED: 
1.  BP, PR , Temperature, RR hourly in both groups. 
2.  Systolic B.P <100 mm of Hg or P.R > 100 or increase in 
temperature will be reported. 
3.  Adverse effects are carefully monitored. 
4.  Fetal heart rate should be monitored hourly in the initial hours of          
Stablisation and fourth hourly for the first 48 hours. 
ACHIEVEMENT OF TOCOLYSIS: 
In this study achievement of tocolysis is considered when the 
contraction stops with 20 mg of transdermal nitroglycerin or 40 mg of 
nifedipine and the pregnancy is prolonged for atleast 48 hours. 
FALIURE OF ACHEIVEMENT OF TOCOLYSIS: 
When the contraction does not stops with 20 mg of transdermal  
patch of nitroglycerine and 40 mg of nifedipine and inability to prolong 
the pregnancy for atleast 48 hours . 
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OUTCOME ARE NOTED AS : 
o Delay in the delivery for 48 hrs, 7 days, and more than 7 days. 
o Gestational age of delivery. 
o Any side effect of each drug. 
o Neo natal out come. 
o Birth weight 
o Respiratory distress. 
o Need and duration of NICU care. 
o Neonatal complication. 
o Perinatal mortality 
Hence this study confines itself to the comparison of two drugs 
namely transdermal patch of nitroglycerine and oral nifedipine in 
prolongation of pregnancy for atleast 48 hours and studying the maternal 
and fetal effects. 
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TOCOLYTIC THERAPY FOR PRETERM LABOUR 
- Women at 28 to 37 weeks of gestation presenting with preterm 
labour. 
- Regular painful uterine contractions(3/10 min). 
- Progressive cervical changes like effacement and dilatation (<4cm) 
GROUP I    GROUP II 
( NITROGYLCERINE 
GROUP) 
 
   (NIFEDIPINE 
GROUP) 
Apply single patch 
(10 mg) 
   administer 20 mg 
oral  nifedipine stat 
followed by 20 mg 
8
th
 hourly 
 
start corticosteroid 
therapy 
 
   start corticosteroid 
therapy 
 
active uterine 
contractions after 1 hr 
 No response as indicated 
by persisting uterine 
contractions and 
progressive cervical 
changes 
 
 active uterine 
contractions after 1 
hr 
 
 
apply second patch 
(20mg) 
 
 Allow to go in to labour  Administer another 
20 mg of nifedipine 
 
favourable response 
 
   favourable response 
 
replace with same no of 
patches after 24 hours 
 
   continue tocolytic for  
48 hours 
stop tocolytic therapy 
after total of 48 hrs since 
admission 
 
   stop oral nifedipine 
after 48 hrs 
Bed rest  
 
   Bed rest 
Followup    Followup 
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NITRO GLYCERINE PATCH USED IN THIS STUDY 
 
                                                  
  
RESULTS AND OBSERVATION 
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RESULTS AND OBSERVATIONS 
AGE DISTRIBUTION 
TABLE - 1 
 
AGE IN YRS 
NTG GROUP NIFEDIPINE 
GROUP 
NO % NO % 
<19 YRS 9 9.27% 13 13.4% 
20-29 YRS 78 80.4% 82 84.5% 
>30YRS 2 2.06% 2 2.06% 
 
 The incidence of preterm labour is about 9.27% in<19 yrs in NTG 
group and 13.4% in nifedipine group. In the 20 to 29 yrs category the 
incidence is 80.4% in the NTG group and 84.5% in the nifedipine 
group.but above the age of 30 years the incidence is 2.06% both in NTG 
and nifedipine group. The mean age in the NTG group 22.86 and 
nifedipine 22.32. Maximum incidence occurs in the age group of 20 to  
29 yrs. 
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AGE DISTRIBUTION 
 
 
 
 
                                 
  
0.00%
10.00%
20.00%
30.00%
40.00%
50.00%
60.00%
70.00%
80.00%
90.00%
<19 years 20 - 29
years
> 30 years
9.27% 
80.40% 
2.06% 
13.40% 
84.50% 
2.06% 
NTG GROUP
NIFEDIPINE
GROUP
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PARITY 
TABLE - 2 
 
 
 
PARITY 
 
NTG GROUP 
 
NIFEDIPINE 
GROUP 
 
NO 
 
% 
 
NO 
 
% 
 
 
PRIMI 
 
 
 
60 
 
 
61.85% 
 
 
65 
 
 
67.01% 
 
GRAVIDA 2 
 
29 
 
29.89% 
 
24 
 
24.74% 
 
GRAVIDA 3 AND 
ABOVE 
 
8 
 
8.24% 
 
9 
 
9.27% 
 
 The incidence  in primi is 61.85% in NTG group and 67.01% in 
nifedipine group and in 2
nd
 gravid incidence is 29.89% in NTG group and 
24.74% in nifedipine group  in multigravida incidence is 8.24% in NTG 
group and 9.27% in nifedipine group. Maximum incidence is in 
primigravida. 
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PARITY 
 
 
 
 
 
 
 
0.00%
10.00%
20.00%
30.00%
40.00%
50.00%
60.00%
70.00%
Primi Gravida
2
Gravida
3 >
61.85% 
29.89% 
8.24% 
67.01% 
24.74% 
9.27% 
NTG GROUP
NIFEDIPINE
GROUP
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PREDISPOSING  FACTORS 
TABLE - 3 
 
 
PREDISPOSING 
FACTOR 
 
NTG  GROUP 
 
NIFEDIPINE 
GROUP 
 
NO 
 
% 
 
NO 
 
% 
 
H/O  PREV PRETERM 
 
10 
 
10.3% 
 
8 
 
8.24% 
 
 
 
H/O  PREV 
ABORTION 
 
8 
 
8.24% 
 
11 
 
11.34% 
   
 
10.3% and 8.24% had history of previous preterm labour in NTG 
group and nifedipine group respectively. 8.24% and 11.34% had previous 
history of one or more abortions. 
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PREDISPOSING  FACTORS 
 
                        
                                             
  
0.00%
2.00%
4.00%
6.00%
8.00%
10.00%
12.00%
HG/O PREV
PRETERM H/O PREV
ABORTION
10.30% 
8.24% 8.24% 
11.34% 
NTG GROUP
NIFEDIPINE
GROUP
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GESTATIONAL AGE 
TABLE - 4 
 
 
AGE IN WEEKS 
NTG GROUP NIFEDIPINE 
GROUP 
 
NO 
 
% 
 
NO 
 
% 
 
 
28 – 32 WEEKS 
 
45 
 
46.4% 
 
39 
 
40.2% 
 
32- 34 WEEKS 
 
41 
 
42.26% 
 
43 
 
44.33% 
 
34-36 WEEKS 
 
11 
 
11.34% 
 
5 
 
5.15% 
 
 46.4% and 40.2% of preterm labour is observed in gestational age 
between 28   to  32 weeks ,42.26% and 44.33% of preterm labour observed 
in 32 to 34 weeks  ,11.43% and  5.15% was observed in 34 to 36 weeks in 
NTG patch group and nifedipine group respectively. 
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GESTATIONAL AGE 
 
 
 
 
 
 
 
 
0.00%
5.00%
10.00%
15.00%
20.00%
25.00%
30.00%
35.00%
40.00%
45.00%
50.00%
NTG GROUP
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CERVICAL DILATATION 
TABLE - 5 
 
CD IN CMS 
 
NTG GROUP 
 
 
NIFEDIPINE GROUP 
 
NO 
 
% 
 
NO 
 
% 
 
 
           1 
 
 
28 
 
 
28.86% 
 
 
28 
 
 
28.86% 
 
 
           2 
 
 
42 
 
 
43.29% 
 
 
38 
 
 
39.17% 
 
 
          3 
 
 
27 
 
 
27.83% 
 
 
31 
 
 
31.95% 
 
           The cervix was 1 cm dilated in 28.86%  both in NTG and nifedipine  
group, 2cm dilated in 43.29% and 39.17% in NTG group and nifedipine 
group respectively and 27.83% and 31.95 % in 3 cm dilated in NTG and 
nifedipine group respectively. 
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CERVICAL DILATATION 
 
 
 
 
 
 
 
28.86% 
43.29% 
27.83% 
0.00%
5.00%
10.00%
15.00%
20.00%
25.00%
30.00%
35.00%
40.00%
45.00%
50.00%
1 2 3
NIFEDIPINE
GROUP
NTG GROUP
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CERVICAL EFFACEMENT 
TABLE - 6 
 
% OF 
EFFACEMENT 
 
NTG GROUP 
 
NIFEDIPINE 
GROUP 
 
NO 
 
% 
 
NO 
 
% 
 
    25% 
 
52 
 
53.60% 
 
49 
 
50.51% 
 
     50% 
 
25 
 
25.77% 
 
27 
 
27.83% 
 
    75% 
 
20 
 
20.61% 
 
21 
 
21.64% 
 
 The cervix was 25% effaced in 53.60% of cases and 50.51%  of 
cases in NTG group and nifedipine group respectively,50% effaced in 
25.77% of cases  and 27.83% of cases  in NTG group and nifedipine group 
respectively , 20.16% and 21.64% of cases in NTG group and nifedipine 
group respectively. 
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CERVICAL EFFACEMENT 
 
 
 
 
 
 
 
 
0.00%
10.00%
20.00%
30.00%
40.00%
50.00%
60.00%
25% 50%
75%
53.60% 
25.77% 
20.61% 
50.50% 
27.8% 
21.60% NTG GROUP
NIFEDIPINE
GROUP
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RESPONSE ACCORDING TO GESTATIONAL AGE 
TABLE - 7 
 
GA IN 
WEEKS 
 
NTG GROUP 
 
NIFEDIPINE GROUP 
 
A 
 
% 
 
NA 
 
% 
 
A 
 
% 
 
NA 
 
% 
 
 
28-32 WEEKS 
 
 
37 
 
 
38.14% 
 
 
8 
 
 
8.24% 
 
 
34 
 
 
35.05% 
 
 
3 
 
 
3.09% 
 
32-34 WEEKS 
 
 
43 
 
 
 
44.32% 
 
2 
 
2.06% 
 
42 
 
43.29% 
 
1 
 
1.03% 
 
34-36 WEEKS 
 
10 
 
10.3% 
 
0 
 
0 
 
3 
 
3.09% 
 
2 
 
2.06% 
 
The prolongation of pregnancy more than 48 hrs is 44.32% and 
43.29% in 32- 34 weeks gestational age group , 38.14% and 35.05% in 28 
to 32 weeks of gestational age and 10.3% and 3.09% in 34 to 36 weeks 
gestational group in NTG and nifedipine group .p value is 0.42. 
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RESPONSE ACCORDING TO GESTATIONAL AGE 
 
 
 
                              
 
 
 
NTG Group(A)
N.GROUP (A)
NTG GROUP (NA)
N.GROUP(NA)
0.00%
50.00%
100.00%
150.00%
200.00%
250.00%
300.00%
350.00%
28 - 32
Weeks
32 - 34
Weeks
34 - 36
Weeks
38.14% 
44.32% 
10.30% 
35.05% 43.29% 
3.09% 
8.24% 
2.06% 0 
3.09 
1.03% 2.06% 
NTG Group(A)
N.GROUP (A)
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ACHIEVE MENT OF TOCOLYSIS 
TABLE - 8 
 
ACHIEVED/NOT 
ACHIEVED 
 
NTG GROUP 
 
NIFEDIPINE 
GROUP 
 
NO 
 
 
 
% 
 
NO 
 
% 
  
ACHIEVED 
 
 87 
 
89.69% 
 
91 
 
93.81% 
 
NOT ACHIEVED 
 
10 
 
10.3% 
 
6 
 
 
 
6.18% 
 
 
 
 The achievement of tocolysis is 89.69 % in NTG group and 93.81% 
in nifedipine group  and the p value is 0.2. 
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ACHIEVE MENT OF TOCOLYSIS 
 
          
 
 
 
 
 
NTG GROUP
NI.GROUP0.00%
20.00%
40.00%
60.00%
80.00%
100.00% 89.69% 
10.30% 
93.81% 
6.18% 
NTG GROUP
NI.GROUP
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RESPONSE ACCORDING TO CERVICAL DILATATION 
TABLE - 9 
 
CD IN CMS 
 
NTG GROUP 
 
NIFEDIPINE GROUP 
 
A 
 
% 
 
NA 
 
% 
 
A 
 
% 
 
NA 
 
% 
 
1 
 
28 
 
28.86% 
 
0 
 
0 
 
27 
 
27.83% 
 
1 
 
1.03% 
 
2 
 
40 
 
41.2% 
 
2 
 
2.06% 
 
38 
 
39.17% 
 
0 
 
0 
 
3 
 
19 
 
19.58% 
 
8 
 
8.24% 
 
26 
 
26.88% 
 
5 
 
5.15% 
 
 
 The patients who delivered after 48 hours in NTG and nifedipine 
group with cervical dilatation  2cm is 41.2% and 39.17% respectively and 
28.86% and 27.83% in patients with 1 cm dilatation respectively.  p value 
is 0.03. 
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RESPONSE ACCORDING TO CERVICAL DILATATION 
 
 
 
 
 
 
 
0.00%
5.00%
10.00%
15.00%
20.00%
25.00%
30.00%
35.00%
40.00%
45.00%
1 2 3
28.86% 
41.20% 
19.58% 
27.83% 
39.17% 
26.88% 
0 
2.06% 
8.24% 
1.03% 
0 
5.15% 
NTG GROUP (A)
NI GROUP (A)
NTG ROUP (NA)
NI GROUP (NA)
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RESPONSE ACCORDING TO CERVICAL EFFACEMENT 
TABLE - 10 
 
CERVICAL 
EFFACEMENT 
 
NTG  GROUP 
 
NIFEDIPINE GROUP 
 
A 
 
% 
 
NA 
 
% 
 
A 
 
% 
 
NA 
 
% 
 
     25% 
 
 
50 
 
51.54% 
 
2 
 
2.06% 
 
47 
 
48.45% 
 
2 
 
2.06% 
 
     50% 
 
23 
 
23.71% 
 
2 
 
 
2.06% 
 
26 
 
26.80% 
 
1 
 
1.03% 
 
      75% 
 
14 
 
14.31% 
 
6 
 
6.18% 
 
18 
 
18.55% 
 
3 
 
3.09% 
 
Among the patients who delivered successfully in the NTG group 
and nifedipine group the cervix was 25 % effaced in 51.54 % and 48.45% 
and  50 % effaced in 23.71% and 26.80% and 75% effaced in 14.31% and 
18.55%  respectively. P value is 0.9. 
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RESPONSE ACCORDING TO CERVICAL EFFACEMENT 
 
 
 
 
 
 
 
 
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
25% 50% 75%
51.54% 23.71% 
14.31% 
48.45% 
26.80% 
18.55% 
20.60% 
2.06% 
6.18% 
NI Group (NA)
NTG Group (NA)
NI.Group (A)
NTG Group(A)
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DURATION OF PROLONGATION 
TABLE - 11 
 
DAYS 
 
NTG GROUP 
 
NIFEDIPINE 
GROUP 
NO % NO % 
 
LESSTHAN 48 HRS 
 
10 
 
10.3% 
 
6 
 
6.18% 
 
48 – 72 HRS 
 
1 
 
1.03% 
 
2 
 
2.06% 
 
72HRS-1 WEEK 
 
3 
 
3.09% 
 
3 
 
3.09% 
 
1WEEK – 2 WEEK 
 
4 
 
4.12% 
 
2 
 
2.06% 
 
>2 WEEK 
 
79 
 
81.44% 
 
84 
 
86.59% 
 
 
 The  prolongation of pregnancy beyond 2 weeks is 86.59% and 
81.44% in nifedipine and nitroglycerine patch group respectively. 
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DURATION OF PROLONGATION 
 
 
 
 
 
 
0.00%
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than 48
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1.03% 
3.09% 4.12% 
81.44% 
6.18% 
2.06% 3.09% 2.06% 
86.59% 
NTG Group
NI Group
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MODE OF DELIVERY 
TABLE - 12 
 
MOD 
 
NTG GROUP 
 
NIFEDIPINE GROUP 
 
A 
 
% 
 
NA 
 
% 
 
A 
 
% 
 
NA 
 
% 
 
  VAGINAL 
 
81 
 
83.50% 
 
10 
 
10.3% 
 
83 
 
85.56% 
 
6 
 
6.18% 
 
 
  LSCS 
 
5 
 
5.15% 
 
0 
 
0 
 
6 
 
6.18% 
 
0 
 
0 
 
 85.56% and 83.50% of cases delivered vaginally in nifedipine group 
and nitroglycerine group respectively .p value is 0.985 is insignificant.             
6 cases in nifedipine group underwent LSCS ( lower segment caesarean 
section) 3 cases PROM (premature rupture of membrane) with no response 
to oxytocin and 2 cases for fetal distress with meconium stained liquor and 
1 case with breech in labour. 
          5 cases in NTG group underwent caserean section of these 3 cases 
fetal distress with meconium stained liquor and 2 cases PROM with no 
respon oxytocin.  
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MODE OF DELIVERY 
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MATERNAL MORBIDITY 
TABLE - 13 
 
NTG GROUP 
 
NIFEDIPINE GROUP 
 
 IRRITATION 
 
 
14 
 
  HYPOTENSION 
 
   4 
 
   RASH 
 
1 
 
TACHYCARDIA 
 
12 
 
  HEADACHE 
 
25 
HYPOTENSION, 
TACHYCARDIA 
 
5 
  NAUSEA,VOMITTING  
4 
   
FACIAL FLUSHING 
 
7 
 
 
This table represent the maternal morbidity in both the groups. The 
p value  is   0.0001 which is statiscally significant . no cases of maternal 
mortality.no cases of postpartum hemorrhage noted in both groups. 
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NEONATAL MORTALITY 
TABLE - 14 
 
MOD 
NTG GROUP NIFEDIPINE GROUP 
 
A 
 
NA 
 
A 
 
NA 
 
VAGINAL 
DELIVERY 
 
 2(2.06%) 
 
  5(5.15%) 
 
  1(1.03%) 
 
  3(3.09%) 
 
LSCS 
 
- 
 
- 
 
- 
 
- 
 
         The neonatal mortality was 5.15% in NTG group and 3.09% in 
nifedipine. Not achieved group in vaginal delivery.  No neonatal  mortality 
in caeserian Group. 
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NEONATAL MORTALITY 
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NEONATAL MORBIDITY 
TABLE - 15 
 
MORBIDITY 
NTG GROUP 
NIFEDIPINE 
GROUP 
A NA A NA 
 
BIRTH ASPHYXIA 
 
0 
 
3 
 
0 
 
2 
 
RDS 
 
3 
 
3 
 
2 
 
3 
 
SEPTICEMIA 
 
3 
 
3 
 
2 
 
1 
 
IVH 
 
1 
 
0 
 
1 
 
0 
 
CONGENITAL 
ANOMALIES 
 
- 
 
1 
 
- 
 
- 
 
 
Better neonatal outcome as to the decrease in the presence of 
respiratory distress syndrome and other complication in neonates  is more  
nifedipine success group. 
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NEONATAL MORBIDITY 
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WEIGHT OF BABY AT BIRTH 
TABLE - 16 
 
BIRTH 
WEIGHT 
IN KG 
NTG GROUP NIFEDIPINE GROUP 
A NA A NA 
NO % NO % NO % NO % 
 
       <2 KG 
 
 
4 
 
4.12% 
 
9 
 
9.27% 
 
4 
 
4.12% 
 
3 
 
3.09% 
   2  -   2.5KG 
 
 
28 
 
28.86% 
 
1 
 
1.03% 
 
17 
 
17.52% 
 
2 
 
2.06% 
 
  2.5   -  3 KG  
 
 
45 
 
46.39% 
 
- 
 
- 
 
63 
 
64.94% 
 
1 
 
1.03% 
 
>3kg 
 
9 
 
9.27% 
 
- 
 
- 
 
5 
 
 
5.15% 
 
- 
 
 
 
Among the achieved cases 46.39% and 64.94% found in NTG group 
and in nifedipine group respectively in 2.5 – 3 kg group . >3kg was found 
in 9.27% in NTG group compared to nifedipine group 5.15%. 
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WEIGHT OF BABY AT BIRTH 
 
  
0.00%
5.00%
10.00%
15.00%
20.00%
25.00%
30.00%
35.00%
40.00%
45.00%
50.00%
< 2 Kg 2 - 2.5 Kg 2.5 - 3 Kg > 3 Kg
4.12% 
28.86% 
46.39% 
9.27% 9.27% 
1.03% 0 0 
NTG GROUP 
A
NA
0.00%
10.00%
20.00%
30.00%
40.00%
50.00%
60.00%
70.00%
< 2 Kg 2 - 2.5 Kg 2.5 - 3 Kg > 3 Kg
4.12% 
17.52% 
64.94% 
5.15% 
3.09% 2.06% 1.03% 0 
NIFEDIPINE GROUP 
A
NA
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DOSAGE REQUIRED 
TABLE - 17 
 
NTG GROUP 
 
NIFEDIPINE GROUP 
 
mg 
 
NO 
 
% 
 
mg 
 
NO 
 
% 
 
10 mg 
 
72 
 
74.22% 
 
20 mg 
 
77 
 
79.38% 
 
 
20 mg 
 
 
25 
 
 
25.77% 
 
 
40 mg 
 
 
20 
 
 
20.6% 
 
Among the nitroglycerine group 74.22% required 10 mg and 
25.77% required  20 mg . 79.38% and 20.6% required 20 mg and 40 mg in 
the nifedipine group   Respectively. 
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74.22% 
25.77% 
79.38% 
20.60% 
0.00%
10.00%
20.00%
30.00%
40.00%
50.00%
60.00%
70.00%
80.00%
90.00%
10 mg 20mg
NTG Group
Nifedipine Group
 
 
DOSAGE REQUIRED 
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DISCUSSION 
In our study the range of gestational age was 28 to 37 weeks in other 
studies it was 24 to 32 weeks (Nikolov et al) and 26 to 34 weeks (bekkari 
et al). Gestational Age was from 20 to 26 weeks up to a maximum of 33.5 
weeks to 36weeks in Cochrane metaanalysis by king JF et al 
46
  in 2003. 
In  our study the dosage of nifedipine used is 40 mg of oral 
nifedipine in the first hour followed by 20 mg of maintanence dose 
(papatsonis et al) 
63.
 Bekkari et al 
14 
used nifeidipine of 30 mg of loading 
dose given as 10 mg tablets every 20 min 3 hours later followed by 
maintanence dose of 10 mg of oral nifedipine 6
th
 hourly for 3 days. 
Wani et al 
70
 found the prolongation beyond 2 days to be 91% with 
NTG versus 88% in ritodrine group but in the RNOTT multicentric trial 
NTG showed lower 63% efficacy in prolonging labour beyond 48 hours 
against 71% with ritodrine. 
Nifedipine prolonged pregnancy two days in 80.9% women 
compared to 69.5% in ritodrine  in the study by paptsonis et al.
63
 In  our 
study nifedipine is significantly better in prolonging pregnancy beyond 48 
hours. 
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In the trial by papatsonis et al nifedipine was found to delay the     
childbirth beyond 7 and 14 days in 72.1% and 64.7% patients respectively    
compare to ritodrine group. The mean prolongation of days in this study 
was 27.66 days in  NTG group and 34.653 in the nifedipine group which 
was similar to the results in paptsonis et al.
63 
A number of studies have quoted that nifedipine decreases the 
incidence of RDS similarly smith et al reported the same effect which is 
similarly present in our study. 
The side effects of NTG and ritodrine compared by Lees et al found 
that the only side effect with NTG was headache which is similar with our 
studies papatsonias et al found the incidence of side effects with nifedipine 
to be significantly less than ritodrine. Similarly in our study the incidence 
of side effects are less with nifedipine when compared to nitroglycerine 
group. 
 
 
 
 
SUMMARY 
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SUMMARY 
 In the study with NTG and NIFEDIPINE   n= 97 it was observed 
that Preterm labour is common in primigravida in the age group of 20  to                      
29 years. 
1. There were 43 to 45 % of cases between 32 to 34 weeks.  
2. Previous pretem delivery was found in 10.3 %,previous abortions  
was found in 8.24% in NTG GROUP and 8.24% in NIFEDIPINE 
group. 
3. Failure of tocolysis was more in NTG group when compare to 
nifedipine group. But statistically it was insignificant but when  the 
cervical dilatationwas greater than 3 cm, nifedipine was 
significantly more effective in prolonging pregnancy compare to 
NTG. 
4. The prolongation of pregnancy more than 48 hours was found to be  
more in 32 to 34 weeks in NTG and nifedipine group.    
5. Among the nitroglycerine group 74.22% required 10 mg and 
25.77%  required 20 mg . 79.38% and 20.6% required 20 mg and 40 
mg in the nifedipine group   respectively. 
6. The cervix was 1 cm dilated in 28.86%  both in NTG and nifedipine 
group, 2cm dilated in 43.29% and 39.17% in NTG group and 
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nifedipine group  respectively and 27.83% and 31.95 % in 3 cm 
dilated in NTG and nifedipine group respectively. 
7. The patients who delivered after 48 hours in NTG and nifedipine 
group with cervical dilatation  2cm is 41.2% and 39.17% 
respectively and 28.86% and 27.83% in patients with 1 cm 
dilatation respectively.  p value is 0.03. 
8. The cervix was 25% effaced in 53.60% of cases and 50.51%  of 
cases in NTG group and nifedipine group respectively,50% effaced 
in 25.77% of cases  and 27.83% of cases  in NTG group and 
nifedipine group respectively , 20.16% and 21.64% of cases in NTG 
group and nifedipine group respectively. 
9. Among the patients who delivered successfully in the NTG group 
and nifedipine group the cervix was 25 % effaced in 51.54 % and 
48.45% and  50 % effaced in 23.71% and 26.80% and 75% effaced 
in 14.31% and 18.55%  respectively. P value is 0.9. 
10. Headache and maternal tachycardia were the most common side 
effect.  
11. No maternal mortality. 
 
99 
 
12. The neonatal mortality was 5.15% in NTG group and 3.09% in 
nifedipine. Not achieved group in vaginal delivery.  No neonatal  
mortality in caeserian Group. 85.56% and 83.50% of cases delivered 
vaginally in nifedipine group and nitroglycerine group respectively. 
13. Among the achieved cases 46.39% and 64.94% found in NTG group 
and in nifedipine group respectively in 2.5 – 3 kg group . >3kg was 
found in 9.27% in NTG group compared to nifedipine group 5.15%. 
  
CONCLUSION 
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CONCLUSION 
 It is concluded from the study that oral Nifedipine is better in safety 
and efficacy than transdermal patch of nitroglycerine in prolonging the 
pregnancy. 
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ANNEXURES 
  
ABBREVIATION 
  
ABBREVIATIONS 
I.P NO - In patients number 
OBS.CODE - Obstetric code 
GA - Gestational age 
CD - Cervical dilatation 
MOD - Mode of delivery 
B.Wt - Birth weight 
TOCOLYSIS 
A 
NA 
- 
- 
- 
 
Achieved 
Not achieved 
NICU - Neonatal intensive care unit 
A/SB/ND 
A 
SB 
ND 
- 
- 
- 
- 
 
Alive 
Still birth 
Neonatal death 
V - Vaginal birth 
LSCS - Lower segment caesarean section 
N 
V 
Ff 
I 
- 
- 
- 
- 
Nausea 
Vomiting 
Facial flushing 
Irritation 
H 
R 
RDS 
NTG 
- 
- 
- 
- 
Headache 
Rash 
Respiratory distress syndrome 
Nitroglycerine 
GOA - Gestation on Admission 
GOD - Gestation on Delivery 
LMP - Last Menstrual Period  
EDD - Expected Date of Delivery 
 
 
 
PROFORMA 
  
PROFORMA 
Name         LMP 
Age         EDD 
IP No         POG 
DOA         DOD 
Presenting Complaints 
 
 
Obstetrical History 
 
 
O/E 
General Condition 
Pulse   BP   Weight   Height 
Pallor 
Pedal Edema 
Temperature 
CVS 
RS 
P/A 
P/S (Date & Time) 
P/V (Date & Time) 
Tocolytic therapy received 
Outcome after 48 hours 
 
 
Side Effects reported 
 
 
Subsequent course of pregnancy 
 
1) Any further of preterm pain     Yes/No 
If “Yes”, managed by 
 
2) Any significant antenatal complication 
PIH/APH/PROM 
 
3) Mode of Delivery 
  
Perinatal Outcome Chart 
 
Time of Birth 
 
Date of Birth 
 
Birth Weight 
 
Live Born/Still Born 
 
APGAR score (1, 5, 10 minutes) 
 
Any Congenital Anomaly 
 
Length of Stay in NICU (If Applicable) 
 
History of Respiratory Distress Syndrome 
 
Outcome 
  
Response to Therapy Chart 
 
Name       Age   IP No 
Group I  / Group II 
TIME PULSE BP 
P/A (Uterine 
Contractions 
per 10min) 
FHR 
P/V 
(Bleeding/Leaking) 
IV 
Fluids 
       
       
       
       
       
       
       
       
       
       
       
       
       
       
  
 
CONSENT FORM 
  
PATIENT CONSENT FORM 
Study Details :  Study of tocolytic effects of oral nifedipine Vs  
transdermal nitroglycerine patch  in preterm  
labour. 
 
Study Centre  : Department of Obstetrics and Gynecology 
                                                       R.S.R.M Hospital 
    Stanley Medical College 
    Chennai - 600 001. 
 
Patient may check () these boxes: 
 
I confirm that I have understood the purpose of procedure for the above 
study. I have the opportunity to ask question and all my questions and doubts 
have been answered to my complete satisfaction. 
 
I understand that my participation in the study is voluntary and that I am 
free to withdraw at any time without giving reason, without my legal rights being 
affected. 
 
I understand that the investigator of the clinical study, others working on 
his behalf, the ethical committee and the regulatory authorities will not need my 
permission to look at my health records, both in respect of current study and any 
further research that may be conducted in relation to it, even if I withdraw from 
the study. However, I understand that my identity will not be revealed in any 
information released to third parties or published, unless as required under the 
law. I agree not to restrict the use of any data or results that arise from this study. 
 
I agree to take part in the above study and to comply with the instructions 
given during the study and faithfully cooperate with the study team and to 
immediately inform the study staff if I suffer from any deterioration in my health 
or well being or any unexpected or unusual symptoms. 
I hereby give permission to undergo complete clinical examination and 
questionnaire. 
 
 I hereby consent to participate in this study. 
 
 
 
Signature / Thumb impression:                                      Place:  Date: 
 
Patient Name and Address:  
 
   
 
Signature of Investigator:                                                  Place:         Date Study  
(Investigator’s Name:           
 
ஆராய்ச்சி தகவல் தாள் 
சசன்னை அரசு                              
                                       
                                  
                                                     
          1..            
   2.            (          ) 
நீங்கள் இந்த ஆராய்ச்சியில் பங்ககற்க நாங்கள் விரும்புகிக ாம். 
இந்த ஆராய்ச்சியில் பங்ககற்பதால் தங்களது கநாயின் 
ஆய்வ ிக்னககயா அல்லது சிகிச்னசகயா பாதிக்கப்படாது 
என்பனதயும் சதரிவித்துக் சகாள்கிக ாம். 
இந்த ஆராய்ச்சியின் முடிவுகனள அல்லது கருத்துகனள 
சவளியிடும் கபாகதா அல்லது ஆராய்ச்சியின் கபாகதா தங்களது 
சபயனரகயா அல்லது அனடயாளங்கனளகயா 
சவளியிடமாட்கடாம் என்பனதயும் சதரிவித்துக் சகாள்கிக ாம். 
இந்த ஆராய்ச்சியில் பங்ககற்பது தங்களுனடய விருப்பத்தின் 
கபரில் தான் இருக்கி து. கமலும் நீங்கள் எந்கநரமும் இந்த 
ஆராய்ச்சியில் இருந்து பின்வாங்கலாம் என்பனதயும் 
சதரிவித்துக்சகாள்கிக ாம். 
இந்த சி ப்புப் பரிகசாதனைகளின் முடிவுகனள ஆராய்ச்சியின் 
கபாகதா அல்லது ஆராய்ச்சியின் முடிவின் கபாகதா தங்களுக்கு 
அ ிவிப்கபாம் என்பனதயும் சதரிவித்துக்ககாள்கிக ாம்.  
 
 
ஆராய்ச்சியாளர் னகசயாப்பம்            பங்ககற்பாளர் னகசயாப்பம் 
கததி: 
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1 NANDHINI 21 181 PRIMI 32.2 2 2 25% 37.2 35 V 3.1 - A - A
2 NITHYA 24 33 PRIMI 30.2 3 1 25% 38.2 56 V 2.68 - A - A
3 ASWINI 20 100 G2P1L1 32.6 2 2 50% 35.3 18 V 2.72 H A - A
4 SANDHYA 24 35 G2P1L0 29.3 2 2 25% 36.3 49 V 2.5 I A - A
5 PREETHA 20 265 PRIMI 33.6 3 1 25% 34.3 4 V 2.46 H A 2 A
6 THENMOZHI 19 105 G2P1L1 31.2 3 3 75% 31.3 12 HRS V 1.68 - NA 5 ND
7 ANJALI 25 126 G2P1L1 33.1 2 1 25% 36.2 22 V 2.54 H A - A
8 SARASWATHY 25 179 G2P1L1 30.6 2 1 50% 34.2 24 LSCS 2.12 R A 6 A
9 JEYASHREE 19 329 PRIMI 32.2 2 2 25% 35.2 21 V 2.5 - A - A
10 ADHI 22 171 G2P1L1 35.2 2 2 75% 36.1 6 V 2.86 I A - A
11 SUBBU 21 274 PRIMI 31.2 3 3 25% 37.4 44 V 3.1 H A - A
12 PARVEEN 20 519 PRIMI 32.4 2 3 25% 34.4 14 V 2.18 - A - A
13 SATHYA 18 1726 PRIMI 31.3 2 1 50% 36.2 34 V 2.7 H A - A
14 SHARMILA 21 608 PRIMI 34.3 2 2 25% 38.6 31 V 3 - A - A
15 KALA 27 1763 G3P2L2 28.3 3 2 25% 34.2 40 V 2.45 H A - A
16 UMA 23 3832 PRIMI 32.6                                                  1 50% 37.1 30 V 2.8 I A - A
17 ASWINI 19 3880 PRIMI 34 3 2 75% 35.6 13 V 2.3 - A - A
18 ANJUGAM 29 3890 G2P1L1 29.6 3 2 50% 34.1 30 V 1.9 H A 2 ND
19 JANNAT 21 3928 PRIMI 33.1 2 1 25% 35.2 15 V 2 H A - A
20 RENUGA 25 3855 PRIMI 32.5 2 2 25% 36.5 28 V 2.7 - A - A
21 KALPANA 29 3730 G3P2L2 32.1 2 2 25% 36.2 29 LSCS 2.24 I A 2 A
22 RATHNA 20 3868 G2P1L1 33.4 2 1 25% 35.1 11 V 2.3 - A - A
23 KALAI 24 3734 PRIMI 34.2 3 3 50% 37.2 21 V 3 - A - A
24 MEGALA 23 3866 G3P2L1 30.3 2 2 25% 36.1 35 V 2.45 H A 1 A
25 PADMA 23 3981 PRIMI 31.4 3 2 75% 32.2 5 V 1.75 - A 2 D
26 JOTHI 25 3628 PRIMI 30 2 1 25% *  * * * * * * *
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27 KALAIYARASI 27 3833 PRIMI 32.4 2 1 25% 35.6 23 V 2.4 H A - A
28 VENNILLA 20 1648 PRIMI 33.1 3 2 50% 37.2 29 V 2.5 I A - A
29 PREMAKUMARI 21 1481 PRIMI 34 2 3 25% 36.4 18 V 2.35 - A - A
30 SUMATHY 23 3896 G3P2L2 28.2 3 3 75% 28.3 24 HRS V 1.1 H NA SB
31 LAKSHMI 28 554 PRIMI 32.1 2 1 50% 35.1 21 V 2.5 - A - A
32 SINDHUMATHI 20 3920 PRIMI 31.6 2 2 25% 34.6 21 LSCS 2.1 - A - A
33 KALPANADEVI 24 3866 PRIMI 34.5 3 1 50% 38.2 25 V 3.2 I A - A
34 CHITRA 24 3866 G2AI 28.2 3 3 75% 36.2 56 V 2.75 H A - A
35 SANGEETHA 23 4665 PRIMI 29.6 3 1 25% 32.1 16 V 1.9 A 5 A
36 VAIDESHWARI 24 3823 PRIMI 32.5 2 2 25% 33 1 V 1.8 - A 6 ND
37 NASREEN 27 8471 PRIMI 31.6 2 3 75% 37.6 42 V 2.5 - A - A
38 SUGANYA 22 3935 PRIMI 33.5 3 2 25% 36.2 18 V 2.45 - A - A
39 VIJAYALAKSHMI 20 3938 PRIMI 34.6 2 2 25% 37.2 17 V 2.5 - A - A
40 GEETHA 23 3782 PRIMI 32.3 3 3 75% 36.3 28 V 2.8 - A - A
41 SAMUNDEESHWARI 26 3556 PRIMI 31.4 2 2 25% 37.4 42 LSCS 2.9 - A 1 A
42 INDHUMATHI 24 4006 G2P1L1 30.6 3 2 50% 36.6 42 V 2.6 - A - A
43 PREMAKUMARI 24 3733 PRIMI 28.4 2 3 25% 28.5 1 V 1.06 H NA - SB
44 SIVARANJANI 21 4489 G2P1L1 31.2 2 2 25% 37.6 47 V 2.7 - A - A
45 RATHNA 20 3868 G2P1L1 30.5 2 2 50% 34.2 25 V 2.3 I A 6HRS A
46 KANITAMIL 23 8624 PRIMI 33.2 2 2 25% 38.2 35 V 2.8 H A - A
47 AMUL 28 4013 G3P1L1A1 32.2 3 3 50% 35.2 21 V 2.4 - A - A
48 JANNAT 21 3928 PRIMI 33.2 3 2 25% 34.4 9 V 2 H A 4 A
49 AYESHA 19 4170 PRIMI 33.5 2 1 25% 35.6 15 V 1.8 - A 7 A
50 RENUGA 26 3856 G3P2L2 31.5 2 1 25% 36.5 35 V 2.7 - A - A
51 HAMEEDHA 18 3986 PRIMI 28.6 3 1 75% 38.6 66 V 2.9 - A 7 A
52 MANOJA 21 8413 PRIMI 29.6 3 2 25% 36.6 49 V 2.8 - A - A
53 MEENA 24 8509 PRIMI 32.2 3 2 50% 36.2 28 V 2.5 - A - A
54 JANAKI 24 4726 G2A1 31.6 3 3 75% 32 22HRS V 2 NA - A
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55 RAMADEVI 21 4276 PRIMI 33.3 2 2 25% 36.3 21 V 2.4 - A - A
56 ASWINI 20 4048 G2A1 30.3 2 1 50% 36.2 43 V 2.6 - A - A
57 KAVITHA 20 8443 PRIMI 34.2 3 2 75% 37.2 21 V 2.8 - A - A
58 JEYASHREE 22 3263 PRIMI 28.2 3 2 50% * * * * * * * *
59 JAMUNA 26 8276 G2P1L1 31.4 3 1 75% 31.5 24HRS V 1.9 - NA 6 A
60 USHA 19 3791 G2P1L1 33.1 3 2 50% 35.2 15 V 2.49 A - A
61 SATHYA 26 4280 G3P2L1 28.2 3 2 25% 37.2 63 V 3.06 H A - A
62 KANAGA 22 4299 G2P1L1 30.2 2 1 50% 35.6 39 V 3.1 I A - A
63 MALATHI 25 8639 G3P1L1A1 32.5 3 3 25% 37.2 32 V 2.8 - A - A
64 SHANTHI 39 5076 G3P2L1 33.1 3 1 75% 37.2 29 V 2.8 - A - A
65 BHAVANI 22 7271 PRIMI 29.2 2 3 25% 36.2 49 V 2.9 - A - A
66 RENUGA 21 4255 PRIMI 28.6 3 3 25% 36.6 56 V 2.5 H A A
67 YAMUNA 21 4653 G2P1L1 32.6 3 1 25% 37.2 31 V 3.2 I A -- A
68 UMA 22 7705 PRIMI 28.6 2 2 50% 34.2 38 V 2.4 - A - A
69 RANJINI 23 5609 G2P1L1 31.2 3 1 25% 35.2 28 V 2.3 - A - A
70 SONIYA 21 4752 G2A1 32.3 3 1 25% 36.2 27 V 2.7 - A - A
71 TAMILVANI 23 13046 G2A1 34.5 3 2 50% 38.2 24 V 2.45 - A - A
72 MARIVALLI 22 11207 PRIMI 30.6 3 3 75% 36.2 38 V 2.8 - A - A
73 RENUGA 25 4369 G2P1L1 28.5 3 2 25% 35.4 30 V 2.05 - A - A
74 MADHAVI 23 7269 PRIMI 32.1 2 3 75% 36.1 28 V 2.6 I A - A
75 GOWTHAMI 22 7419 PRIMI 30.5 2 3 50% 36.4 40 V 2.7 H A - A
76 KRISHNAPRIYA 20 13168 PRIMI 34.6 3 2 50% 36.6 14 V 2.8 H A - A
77 MANJU 20 7826 PRIMI 31.2 3 3 75% 31.3 18HRS V 1.9 I NA - A
78 RAGINI 20 8879 G2A1 31.3 2 3 25% 36.2 34 V 2.2 - A 2 A
79 RAMEE 22 8160 PRIMI 32.3 3 2 50% * * * * * * * *
80 JEEVA 20 13083 PRIMI 34.3 2 3 25% 38.2 27 V 2.7 I A A
81 SAFIYA 20 8113 PRIMI 30.2 3 3 75% 30.3 18HRS V 1.2 H NA A
82 FARIDHA 22 4836 PRIMI 32.6 3 3 25% 36.4 26 V 2.8 - A A
S.
N
O
N
A
M
E
A
G
E
IP
.N
O
O
B
S.
C
O
D
E
 G
O
A
 C
O
N
T
R
A
C
T
IO
N
S/
1
0
 M
IN
C
D
 I
N
  C
M
S
E
F
F
A
C
E
M
E
E
N
T
G
O
D
N
O
 O
F
 D
A
Y
S
M
O
D
B
.W
T
SI
D
E
E
F
F
E
C
T
T
O
C
O
L
Y
SI
S
N
IC
U
A
/S
B
/N
D
83 AISWARYA 18 4529 PRIMI 31.2 3 2 50% 34.4 23 V 2.11 H A A
84 PRIYA 21 8766 PRIMI 30.6 3 1 25% 36.4 40 V 2.8 - A A
85 MABHUNI 32 12946 G2P1L0 31.2 3 1 25% 35.6 28 V 2.2 - A A
86 RAJINI 20 10766 PRIMI 32.1 3 1 50% 37.2 36 LSCS 3.1 H A A
87 SANDHYA 22 9866 PRIMI 33.4 3 2 25% 36.2 19 V 2.5 - A A
88 KUDIYARASI 22 2296 PRIMI 34.2 2 3 25% 37.3 22 V 2.8 I A A
89 MADHAVI 22 10762 PRIMI 30.6 3 1 50% # # # # # A # #
90 UMA 22 7806 G2A1 32.6 3 2 25% 37.2 31 V 2.9 - A A
91 ROOPAVATHY 29 12737 G2P1L1 35.2 2 1 25% 38.6 25 V 2.6 H A A
92 GAJALAKSHMI 28 10733 PRIMI 34.3 3 2 75% 37.3 28 V 2.7 - A A
93 VIJAYALAKSHMI 23 12759 PRIMI 33.5 3 3 25% 34.2 3 V 2.3 H A A
94 JAMUNA 22 4756 PRIMI 29.6 2 3 50% 29.6 20HRS V 1.2 - NA 1 ND
95 JASMINE 23 4858 G2P1L1 30.1 3 2 75% 37.2 50 LSCS 2.8 I A A
96 DEVI 29 12555 PRIMI 29.2 2 2 25% 36.2 42 V 2.8 - A A
97 MENAGA 23 4649 G2P1L1 31.2 3 3 50% 35.3 29 V 2.18 H A A
98 JANAKI 23 8472 PRIMI 28.5 2 1 75% 37.5 61 V 2.8 - A A
99 RITA 24 9650 PRIMI 29.2 3 2 25% 37.5 59 V 2.9 - A A
100 VIJAYALAKSHMI 22 13192 PRIMI 32 2 2 25% 32.4 12HRS V 1.8 NA 6 A
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1 SATHYA 18 349 PRIMI 28.2 2 1 25% 34.2 42 V 1.5 A 20 A
2 PRIYA 20 114 PRIMI 32.2 2 2 25% 36.5 31 V 2.75 A - A
3 DEEPA 25 484 PRIMI 33.1 3 2 50% 36.4 24 LSCS 2.2 HYPO A - A
4 ARUNASANDHYA 22 725 PRIMI 34 2 3 75% 37.4 23 V 3 A - A
5 VENILA 20 1648 PRIMI 32.1 3 1 25% 35.6 26 V 2.59 TACY A - A
6 GAYATHRI 20 1789 PRIMI 28.2 2 3 75% 36.6 74 V 2.3 A - A
7 RUKASAR 20 2015 PRIMI 33.2 3 2 50% 37.2 28 V 2.6 Ff A - A
8 LAKSHMI 19 288 PRIMI 30.1 2 2 25% 36.3 44 LSCS 2.2 A 2 A
9 SAKTHIDEVI 19 450 PRIMI 31.4 3 2 25% 36.6 37 V 2.7 TACY A - A
10 LAKSHMI 28 554 PRIMI 32.5 2 2 50% 37.3 32 V 2.5 A - A
11 RATHAN 20 3868 G2PIL1 33.4 3 1 50% 37.4 28 V 2.3 TACHY,HYPO A - A
12 MEHATAJ 20 3788 G3A2 33.5 3 2 25% 37.5 28 V 2.5 A - A
13 DEVI 26 3951 G2P1L1 32.6 3 1 75% 37.2 31 V 3 A - A
14 SAGAYAMARY 21 4280 PRIMI 39.5 3 2 75% 6HRS 6HRS V 1.02 NA - SB
15 PREETHA 20 3864 PRIMI 31.6 3 1 25% 36.6 35 V 2.8 A - A
16 VALARMATHI 21 4296 PRIMI 30.6 2 2 25% 37.2 45 V 2.4 Ff A - A
17 LAKSHMI 21 4399 G2P1L1 32.5 2 3 50% 38.2 38 V 2.8 A - A
18 YOGESHWARI 22 4388 PRIMI 32.6 3 1 75% 38.3 39 V 2.9 A - A
19 PRIYA 21 4323 G2A1 33.4 2 2 25% 37.4 28 V 2.7 TACY A - A
20 KANAGA 25 4122 PRIMI 34.2 3 3 75% 36.6 16 V 2.5 A A
21 NADHIYA 21 4325 G2P1L1 28.2 2 1 25% * * * * * * * *
22 JEYALAKSHMI 27 5039 PRIMI 28 3 2 50% 37.1 72 V 2.8 A - A
23 SHANMUGAPRIYA 18 4681 PRIMI 30.1 2 3 25% 36.6 47 V 2.45 A - A
24 SONIYA 21 4752 G2A1 31.2 3 1 50% 36.4 37 V 2.7 HYPO,TACY A - A
25 VISALI 19 4750 G2P1L1 32.3 2 2 50% 37.2 34 V 2.9 A - A
26 RANJANI 25 4960 G2P1L1 33.4 3 3 75% 38.2 33 V 2.8 A - A
27 GEETHA 28 5002 G3P1L1A1 30.2 2 1 25% 37 47 V 2.7 A - A
28 ASWINI 20 4048 PRIMI 31.3 2 2 50% 36.6 38 V 2.6 TACY A - A
29 MUMTAJ 22 4607 PRIMI 33.5 2 3 50% 38 30 V 2.79 Ff A - A
30 RAHEMUNISHA 19 5147 PRIMI 28.2 3 3 25% 37.2 63 V 2.9 A - A
31 MOHANA 23 4649 PRIMI 30.2 2 1 25% 36.6 46 V 2.7 TACY,HYPO A - A
32 DILMAYA 19 4888 PRIMI 33.2 3 1 25% 38.2 35 V 2.9 A - A
33 SIVARANJANI 22 7338 PRIMI 30.2 3 2 50% 37.2 42 V 2.5 A - A
34 JEYANTHI 23 7375 G2P1L0 31.3 3 3 25% 36.6 38 V 2.7 TACY A - A
35 SUGANTHI 23 4381 G2P1L1 32.4 3 1 25% 37.3 34 V 2.6 A - A
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36 KAYALVIZHI 25 7384 G3P1L1A1 33.6 3 1 50% 36.6 21 V 2.9 A - A
37 SASIKALA 28 8111 PRIMI 30.3 3 2 75% 35.2 36 V 2.5 Ff A - A
38 SARALA 30 3663 PRIMI 29.2 3 3 25% 6HRS 6HRS V 1.2 NA - SB
39 LEELA 21 4856 PRIMI 28.5 2 3 50% 37.3 61 V 2.6 TACY A - A
40 VAIDHEKI 21 4242 PRIMI 30.5 3 2 75% 36.5 42 V 2.8 A A
41 RADHIKA 20 2962 PRIMI 32.5 2 1 25% * * * * * * * *
42 SANDHYA 22 7418 PRIMI 33.2 3 1 25% 36.3 22 V 2.3 A 2 A
43 DATCHAYINI 26 4160 G2P1L0 34.3 2 2 25% 37.2 20 V 2.8 TACY,HYPO A A
44 SANGEETJA 18 5164 PRIMI 30.2 3 3 75% 18HRS 18HRS V 1.6 TACY NA - D
45 SABARKANYAS 22 4851 G2P1L1 31.5 3 1 50% 34.3 19 V 1.9 A 10 A
46 VARALAKSHMI 20 4345 PRIMI 32.6 3 2 25% 37.2 31 V 2.9 A 7 A
47 NANDHINI 18 7450 PRIMI 33.3 3 3 25% 36.4 22 V 2.7 A - A
48 NALINI 21 7378 G3A2 32.4 2 3 50% 37.1 32 V 2.8 N,V A - A
49 SHOBANA 25 4132 PRIMI 33.2 3 2 225% 36.2 21 V 2.9 A - A
50 BANUPRIYA 20 7322 PRIMI 28.5 3 1 50% 37.2 60 LSCS 2.9 A - A
51 PADMAVATHY 24 5035 G3P1L1A1 30.3 2 1 25% 36.2 41 V 2.6 Ff A - A
52 MAHALAKSHMI 25 4126 G2P1L1 28.2 3 2 25% 36.1 55 V 2.8 TACY A - A
53 JEYANTHI 24 7427 G3P1L1A1 32.4 2 3 25% 37.2 33 V 2.74 A - A
54 NARMADHA 18 9650 PRIMI 33.1 3 2 25% # # # # A
55 DESARANI 23 5007 G2P1L1 32.3 3 3 25% 37.5 37 V 3.1 A - A
56 DHANALAKSHMI 21 4729 PRIMI 33.6 3 1 75% 39.2 38 LSCS 2.8 N,V A - A
57 RAJALAKSHMI 21 4718 PRIMI 31.2 3 1 25% 37.1 41 V 2.75 A 4 A
58 BAGYAM 23 4682 G4P2L1A1 32.4 2 2 25% 36.6 30 V 2.3 A - A
59 BEGUM 21 3623 PRIMI 35.5 2 3 25% 8HRS 8HRS V 2.1 TACY NA 3 A
60 KARUNA 29 3904 G2A1 30.6 3 2 75% 36.3 39 V 2.6 HYPO A A
61 NAGASUDHA 22 3120 G3P2L1 28.2 2 2 25% * * * * * * * *
62 TAMILARASI 20 4680 PRIMI 30.2 3 1 25% 36.2 42 V 2.6 TACY A - A
63 UMAMAHESHWARI 21 3853 G2P1L1 32.5 3 2 50% 37.2 32 V 2.8 A - A
64 SAMUNDEESHWARI 18 4742 PRIMI 31.5 3 3 25% 36.3 33 V 2.6 HYPO A - A
65 SUMATHI 37 3805 G2P1L1 33.4 3 3 75% 37.2 26 V 2.8 A - A
66 JEYASUDHA 24 8107 G2P1L1 34.2 3 2 25% 38 26 V 2.9 HYPO A - A
67 AMRITHA 21 7507 PRIMI 33.5 2 1 50% 37.6 29 V 3.1 TACY A - A
68 KALAIYARASI 27 3833 PRIMI 31.6 2 2 25% 36.5 34 V 2.5 A 2 A
69 RASEENA 24 8520 PRIMI 32.6 3 3 50% 37.2 31 V 2.5 A - A
70 SUMATHI 25 8711 PRIMI 30.3 2 1 75% 37.2 48 LSCS 2.6 A - A
71 JEGADEESHWARI 24 7816 G2A1 31.4 3 2 25% 36.6 37 V 2.9 TACY A - A
72 INDHUMATHI 20 4218 PRIMI 32.5 3 3 50% 37.5 35 V 2.4 Ff A - A
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73 UDHAYAMATHI 20 7855 PRIMI 33.4 2 1 50% 8HRS 8HRS V 1.9 NA 3 A
74 CHARUMATHI 26 4203 G2P1L1 28.6 3 2 25% 35.6 35 V 2.3 HYPO,TACY A - A
75 NITHYA 22 12061 PRIMI 30.2 2 3 25% 36.2 42 V 2.6 A - A
76 AMUDHA 21 5129 G2P1L0 29.6 3 3 75% 37.2 52 V 2.8 A - A
77 BHARATHI 21 8793 PRIMI 30.4 3 2 25% 36.6 44 V 2.7 A - A
78 NAGAMMA 22 4991 G3P2L2 32.6 2 1 50% 38.2 38 V 3.1 A - A
79 THULASI 20 12050 PRIMI 30.6 3 3 25% 36.6 42 V 2.8 Ff A - A
80 GAYATHRI 24 4832 PRIMI 32.5 2 2 25% 36.2 24 V 2.9 A - A
81 LAVANYA 22 8686 G2P1L1 34.2 3 1 25% 38.2 28 V 2.7 A - A
82 RAJASHRI 20 9890 PRIMI 30.2 3 3 50% # # # # A # #
83 MAHESHWARI 24 12176 PRIMI 28.2 3 2 75% 36.3 57 V 2.7 A - A
84 PRABHAVATHI 21 4829 PRIMI 33.2 3 2 25% 37.2 28 V 2.5 A 2 A
85 SAROJINI 22 8529 PRIMI 32.4 3 3 25% 37.5 36 V 3.1 A - A
86 SWEDHA 19 4491 PRIMI 30.2 2 1 25% 36.6 46 V 2.8 N,V A - A
87 NISHANTHI 21 8523 PRIMI 30.6 2 1 75% 36.5 41 V 2.6 A - A
88 GOMATHI 19 8650 PRIMI 34.3 2 3 25% 6HRS 6HRS V 2 NA 3 A
89 EZHIL 22 6650 PRIMI 32.5 3 2 50% 37.2 31 LSCS 2.8 N,V A - A
90 RAJINIDEVI 20 7870 PRIMI 35.2 3 2 50% 39.2 28 V 2.8 A - A
91 BHAVANI 27 12350 G2P1L1 30.3 3 3 25% 37.5 51 V 2.9 A - A
92 SASIKALA 28 9570 PRIMI 32.4 3 1 25% 37.2 33 V 2.8 A - A
93 JEYA 26 10721 PRIMI 31.2 2 2 75% 38.2 49 V 3 A - A
94 SANDHYA 20 12580 PRIMI 33.6 3 3 25% 37.5 27 V 2.8 A - A
95 NADHIYA 22 11750 PRIMI 32.5 2 3 25% 37.4 36 V 2.9 A - A
96 VEMBAVALLI 21 9592 PRIMI 30.2 3 1 50% 37.2 49 V 2.8 A - A
97 REVATHI 21 12965 PRIMI 29.6 2 2 75% 37.3 53 V 2.7 A - A
98 KOKILLA 22 9890 G2P1L1 31.2 3 3 25% 36.3 36 V 2.8 A - A
99 SANDHYA 24 7856 G2A1 32.3 2 3 25% 37.2 34 V 2.9 A - A
100 MANJU 28 12860 PRIMI 33.4 3 2 75% 36.4 21 V 2.6 A A
TOCOLYSIS-A / NA A/SB/D V- VAGINAL N - NAUSEA
A-ACHIEVED A-ALIVE LSCS - LOWER SEGMENT CAESERAN SECTION V - VOMITTING
NA - NOT ACHIEVED SB -STILL BIRTH ********************** - LOSS OF FOLLOW HYPO - HYPOTENSION
D -DEATH ############### - STILL CONTINUING TACY - TACY CARDIA
HRS - HOURS     PREGNANCY Ff - FACIAL FLUSHING
G - GRAVIDA L - LIVE
P - PARA
